| Role of B cells as antigen presenting cells I Rastogi, D Jeon, JE Moseman, A Muralidhar, HK Potluri, DG McNeel Frontiers in immunology 13, 954936, 2022 | 98 | 2022 |
| Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer GM Botting, I Rastogi, G Chhabra, M Nlend, N Puri PloS one 10 (8), e0136155, 2015 | 50 | 2015 |
| Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer I Rastogi, S Rajanna, A Webb, G Chhabra, B Foster, B Webb, N Puri Biochemical and biophysical research communications 477 (4), 937-944, 2016 | 33 | 2016 |
| Vaccines as treatments for prostate cancer I Rastogi, A Muralidhar, DG McNeel Nature Reviews Urology 20 (9), 544-559, 2023 | 19 | 2023 |
| Treatment combinations with DNA vaccines for the treatment of metastatic castration-resistant prostate cancer (mCRPC) M Gamat-Huber, D Jeon, LE Johnson, JE Moseman, A Muralidhar, ... Cancers 12 (10), 2831, 2020 | 18 | 2020 |
| EGFR and c-Met inhibitors are effective in reducing tumorigenicity in cancer A Stone, K Harrington, M Frakes, K Blank, S Rajanna, I Rastogi, N Puri Journal of Carcinogenesis and Mutagenesis, 2014 | 17 | 2014 |
| Current molecularly targeting therapies in NSCLC and melanoma S Rajanna, I Rastogi, L Wojdyla, H Furo, A Kulesza, L Lin, B Sheu, ... Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2015 | 16 | 2015 |
| c-Met: A Potential Target for Current Non-Small-Cell Lung Cancer Therapeutics A Stone, S Rajanna, I Rastogi, J Cruz, K Harrington, K Blank, M Frakes, ... Chemotherapy, 2014 | 4 | 2014 |
| From Electronic Sequence to Purified Protein Using Automated Gene Synthesis and In Vitro Transcription/Translation C Chiocchini, K Vattem, M Liss, L Ludewig, T Reusch, I Rastogi, B Webb, ... ACS Synthetic Biology 9 (7), 1714-1724, 2020 | 3 | 2020 |
| Current Molecularly Targeted Therapies against EGFR for Cancer. J C Rastogi, S Rajanna, N Puri Cancer Sci 6, e131, 2013 | 1 | 2013 |
| B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA I Rastogi, DG McNeel Oncoimmunology 12 (1), 2212550, 2023 | | 2023 |
| 1379 Novel backbone-modified analogues of antigenic peptides improve immunogenic capabilities of anti-tumor peptide vaccines I Rastogi, R Gibadullin, SH Gellman, D McNeel Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 271 B cell primed CD8 T cells generate similar phenotype, function and anti-tumor responses to DC primed CD8 T cells I Rastogi, D McNeel Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Genetic diversity of medically important scorpions of the genus Centruroides (Buthidae) from Panama including two endemic species S Escudero-Sanjur, E Castro-Perez, HA De Patiño, I Rastogi, CW Ramos Journal of Genetics 101 (2), 32, 2022 | | 2022 |
| B cells licensed by DCs are primary antigen presenting cells for DNA plasmid upon passive uptake I Rastogi, DG McNeel The Journal of Immunology 208 (1_Supplement), 102.09-102.09, 2022 | | 2022 |
| Role of B Cells as Antigen Presenting Cells After Passive Uptake of Plasmid DNA I Rastogi The University of Wisconsin-Madison, 2022 | | 2022 |
| B cells serve as primary antigen presenting cells for DNA vaccines I Rastogi, D McNeel, I Rastogi JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| Epithelial mesenchymal transition and its role in TKI resistant NSCLC cell lines I Rastogi, T Iderzorig, G Chhabra, GM Botting, A Webb, B Foster, B Webb, ... Cancer Research 76 (14_Supplement), 1599-1599, 2016 | | 2016 |
| Mechanism of c-Met TKI resistance and role of epithelial mesenchymal transition in melanoma S Rajanna, I Rastogi, S Palani, N Puri Cancer Research 75 (15_Supplement), 347-347, 2015 | | 2015 |
| Mechanism of TKI resistance and role of epithelial mesenchymal transition in NSCLC I Rastogi, GM Botting, A Webb, BL Webb, MC Nlend, N Puri Cancer Research 75 (15_Supplement), 337-337, 2015 | | 2015 |
